Spero Therapeutics’ (SPRO) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Spero Therapeutics (NASDAQ:SPRO) in a research report sent to investors on Friday morning,Benzinga reports.

SPRO has been the subject of several other research reports. HC Wainwright lowered their price objective on Spero Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, November 4th. TD Cowen raised shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th.

Spero Therapeutics Stock Performance

Shares of SPRO opened at $1.14 on Friday. Spero Therapeutics has a 52 week low of $1.01 and a 52 week high of $1.89. The stock has a market capitalization of $61.55 million, a price-to-earnings ratio of 16.29 and a beta of 0.63. The stock has a fifty day moving average of $1.29 and a 200-day moving average of $1.36.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in SPRO. Vanguard Group Inc. grew its stake in Spero Therapeutics by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after purchasing an additional 9,675 shares during the period. Acadian Asset Management LLC increased its stake in shares of Spero Therapeutics by 121.8% in the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock valued at $1,310,000 after acquiring an additional 418,742 shares in the last quarter. Murchinson Ltd. increased its stake in shares of Spero Therapeutics by 1.3% in the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock valued at $1,503,000 after acquiring an additional 11,210 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Spero Therapeutics during the 1st quarter valued at $31,000. Finally, Renaissance Technologies LLC boosted its stake in Spero Therapeutics by 14.2% during the second quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock worth $1,269,000 after acquiring an additional 121,492 shares in the last quarter. 25.60% of the stock is owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.